First Regular Session Seventy-third General Assembly STATE OF COLORADO

ENGROSSED

This Version Includes All Amendments Adopted on Second Reading in the House of Introduction

LLS NO. 21-0091.01 Richard Sweetman x4333

SENATE BILL 21-123

SENATE SPONSORSHIP

Ginal and Coram,

HOUSE SPONSORSHIP

McCormick,

Senate Committees Health & Human Services

House Committees

	A BILL FOR AN ACT
101	CONCERNING EXPANDING THE CANADIAN PRESCRIPTION DRUG
102	IMPORTATION PROGRAM TO INCLUDE PRESCRIPTION DRUG
103	SUPPLIERS FROM NATIONS OTHER THAN CANADA UPON THE
104	ENACTMENT OF LEGISLATION BY THE UNITED STATES CONGRESS
105	AUTHORIZING SUCH PRACTICE.

Bill Summary

(Note: This summary applies to this bill as introduced and does not reflect any amendments that may be subsequently adopted. If this bill passes third reading in the house of introduction, a bill summary that applies to the reengrossed version of this bill will be available at http://leg.colorado.gov.)

In 2019, the Colorado general assembly enacted, and the governor subsequently signed into law, the Canadian prescription drug importation

program (program) in the department of health care policy and financing (department). The bill states that the department may expand the program to allow a manufacturer, wholesale distributor, or pharmacy from a nation other than Canada to export prescription drugs into the state under the program if certain conditions are met.

If, upon the satisfaction of these conditions, the department decides to expand the program, the executive director of the department shall notify the president of the senate, the speaker of the house of representatives, and specified legislative committees, of the department's intent to do so. The executive director shall provide the notice at least 30 days before the program is expanded, and the notice may include any recommendations of the department for legislation to amend the program to reflect its expansion.

Be it enacted by the General Assembly of the State of Colorado:

SECTION 1. Legislative declaration. (1) The general assembly finds that:

- (a) The people of the United States pay the highest prescription drug prices in the world, to the detriment of Colorado consumers, employers, and the state;
- (b) The cost of prescription drugs continues to rise faster than any other major component of health care, contributing to the affordability challenge faced by Colorado consumers, employers, and the state;
- (c) Given the COVID-19 pandemic and the resulting economic downturn, the affordability of prescription drugs is more important than ever in the state of Colorado;
- (d) In 2019, the general assembly enacted, and the governor subsequently signed into law, Senate Bill 19-005, which created the Canadian prescription drug importation program in the department of health care policy and financing, which program requires the department, upon approval of the program by the United States secretary of health and human services, to access lower-priced prescription drugs in Canada; and

-2- 123

1	(e) Many other countries have even lower prescription drug prices
2	than Canada, as well as different supplies of specific drugs.
3	(2) Therefore, the general assembly declares that by accessing
4	additional countries' drug supplies through Colorado's drug importation
5	program, Colorado could even further increase access and cost savings
6	associated with the program.
7	SECTION 2. In Colorado Revised Statutes, add 25.5-2.5-208 as
8	follows:
9	25.5-2.5-208. Expansion of program to include additional
10	foreign suppliers - federal action required - notice to general
11	assembly. (1) Notwithstanding any provision of this part 2 to the
12	CONTRARY, THE STATE DEPARTMENT MAY EXPAND THE PROGRAM TO
13	ALLOW A MANUFACTURER, WHOLESALE DISTRIBUTOR, OR PHARMACY
14	FROM A NATION OTHER THAN CANADA TO EXPORT PRESCRIPTION DRUGS
15	INTO THE STATE UNDER THE PROGRAM IF:
16	(a) THE UNITED STATES CONGRESS ENACTS LEGISLATION TO
17	AMEND 21 U.S.C. SEC. 384 OR OTHERWISE ENACTS LEGISLATION TO
18	PERMIT STATES, INCLUDING COLORADO, TO IMPORT PRESCRIPTION DRUGS
19	FROM FOREIGN COUNTRIES OTHER THAN CANADA;
20	(b) A VENDOR, IN CONSULTATION WITH THE STATE DEPARTMENT,
21	HAS IDENTIFIED THE MANUFACTURER, WHOLESALE DISTRIBUTOR, OR
22	PHARMACY AS A SUPPLIER THAT SATISFIES THE REQUIREMENTS OF THE
23	PROGRAM AND THAT WILL EXPORT PRESCRIPTION DRUGS AT PRICES THAT
24	WILL PROVIDE COST SAVINGS TO THE STATE;
25	(c) The manufacturer, wholesale distributor, or
26	PHARMACY IS APPROPRIATELY LICENSED OR PERMITTED UNDER THAT
27	NATION'S LAWS AND REGULATIONS PERTAINING TO THE MANUFACTURING,

-3-

1	DISTRIBUTION, OR DISPENSING OF PRESCRIPTION DRUGS;
2	(d) The manufacturer, wholesale distributor, or
3	PHARMACY IS LOCATED IN A NATION THAT IS APPROVED TO EXPORT
4	PRESCRIPTION DRUGS INTO COLORADO BY THE UNITED STATES
5	SECRETARY OF HEALTH AND HUMAN SERVICES OR BY ANOTHER
6	AUTHORITY THAT IS DESIGNATED FOR SUCH PURPOSE BY FEDERAL LAW;
7	AND
8	(e) THE STATE DEPARTMENT SUBMITS EVIDENCE TO THE PRESIDENT
9	OF THE SENATE, THE SPEAKER OF THE HOUSE OF REPRESENTATIVES, AND
10	THE HEALTH AND HUMAN SERVICES COMMITTEE OF THE SENATE AND THE
11	HEALTH AND INSURANCE COMMITTEE OF THE HOUSE OF REPRESENTATIVES,
12	OR ANY SUCCESSOR COMMITTEES, WHICH EVIDENCE COMPARES THE
13	EXPORTING NATION'S REGULATORY SYSTEM FOR PRESCRIPTION DRUGS TO
14	THE REGULATORY SYSTEM FOR PRESCRIPTION DRUGS ADMINISTERED BY
15	THE UNITED STATES FOOD AND DRUG ADMINISTRATION PURSUANT TO THE
16	FEDERAL ACT AND DEMONSTRATES THAT THE EXPORTING NATION'S
17	REGULATORY SYSTEM IS AS STRINGENT AS THE SYSTEM IN THE UNITED
18	STATES OR OTHERWISE ENSURES THE SAFETY, PURITY, AND POTENCY OF
19	THE PRESCRIPTION DRUGS FROM THE EXPORTING NATION. THE EVIDENCE
20	MUST COMPARE THE REGULATIONS FOR:
21	(I) SECURING THE SUPPLY CHAIN FOR PRESCRIPTION DRUGS;
22	(II) PRESCRIPTION DRUG MANUFACTURING;
23	(III) PRESCRIPTION DRUG LABELING; AND
24	(IV) PRESCRIPTION DRUG TRACKING AND TRACING.
25	(2) IF, UPON THE SATISFACTION OF THE CONDITIONS DESCRIBED IN
26	SUBSECTION (1) OF THIS SECTION, THE STATE DEPARTMENT DECIDES TO
27	EXPAND THE PROGRAM TO ALLOW A MANUFACTURER, WHOLESALE

-4- 123

1	DISTRIBUTOR, OR PHARMACY FROM A NATION OTHER THAN CANADA TO
2	EXPORT PRESCRIPTION DRUGS INTO THE STATE UNDER THE PROGRAM, THE
3	EXECUTIVE DIRECTOR SHALL NOTIFY THE PRESIDENT OF THE SENATE, THE
4	SPEAKER OF THE HOUSE OF REPRESENTATIVES, AND THE HEALTH AND
5	HUMAN SERVICES COMMITTEE OF THE SENATE AND THE HEALTH AND
6	INSURANCE COMMITTEE OF THE HOUSE OF REPRESENTATIVES, OR ANY
7	SUCCESSOR COMMITTEES, OF THE STATE DEPARTMENT'S INTENT TO DO SO.
8	THE EXECUTIVE DIRECTOR SHALL PROVIDE THE NOTICE AT LEAST THIRTY
9	DAYS BEFORE THE PROGRAM IS EXPANDED, AND THE NOTICE MAY INCLUDE
10	ANY RECOMMENDATIONS OF THE STATE DEPARTMENT FOR LEGISLATION TO
11	AMEND THIS PART 2 TO REFLECT THE EXPANSION OF THE PROGRAM.
12	(3) IF THE STATE DEPARTMENT EXPANDS THE PROGRAM IN
13	ACCORDANCE WITH THIS SECTION, AN ELIGIBLE IMPORTER MAY IMPORT A
14	PRESCRIPTION DRUG FROM A FOREIGN SUPPLIER PURSUANT TO THIS
15	SECTION IF THE DRUG THAT IS TO BE IMPORTED IS A PRESCRIPTION DRUG,
16	AS DEFINED IN 21 U.S.C. SEC. 384 (a)(3).
17	SECTION 3. Act subject to petition - effective date. This act
18	takes effect at 12:01 a.m. on the day following the expiration of the
19	ninety-day period after final adjournment of the general assembly; except
20	that, if a referendum petition is filed pursuant to section 1 (3) of article V
21	of the state constitution against this act or an item, section, or part of this
22	act within such period, then the act, item, section, or part will not take
23	effect unless approved by the people at the general election to be held in
24	November 2022 and, in such case, will take effect on the date of the
25	official declaration of the vote thereon by the governor.

-5-